Davendra Mehta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Davendra Mehta has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Ameesh Isath
Mass General Brigham Heart and Vascular Institute and Harvard Medical School , Boston, MA
3 shared publications Ashish Correa
Icahn School of Medicine; St. Luke's-Roosevelt-Mount Sinai, New York, New York, USA
3 shared publicationsDeepak Padmanabhan
Department of Cardiology, Mayo Clinic, Rochester, MN; Department of Electrophysiology, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, KA, India
3 shared publicationsStuthi Perimbeti
Department of Medicine, Mount Sinai Morningside and Mount Sinai West, New York, NY
3 shared publicationsC. Anwar A. Chahal
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, USA
2 shared publicationsChayakrit Krittanawong
Section of Cardiology, Baylor College of Medicine, Houston, TX
2 shared publications
Latest Publications
- 21 November 2025
- Published by Springer Nature
- p. 195-197
Left Atrial Occlusive Devices
- Open Access
- 30 July 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (8) , 101121
Prognostic Significance of Ventricular Rate at Discharge in Patients With Persistent Atrial Fibrillation and HF
- 30 July 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (8) , 101121
Open AccessPrognostic Significance of Ventricular Rate at Discharge in Patients With Persistent Atrial Fibrillation and HF
- 17 November 2022
- Published by Elsevier in Current Problems in Cardiology
- Vol. 48 (3) , 101504
Trends, Burden, and Impact of Arrhythmias on Cardiac Transplant Recipients: A 16-year Nationwide Study
- 17 November 2022
- Published by Elsevier in Current Problems in Cardiology
- Vol. 48 (3) , 101504
Trends, Burden, and Impact of Arrhythmias on Cardiac Transplant Recipients: A 16-year Nationwide Study
- 1 September 2021
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 7 (9) , 1087-1095
Incidence and Predictors of Sudden Cardiac Arrest in Sarcoidosis
- 1 September 2021
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 7 (9) , 1087-1095
Incidence and Predictors of Sudden Cardiac Arrest in Sarcoidosis
- 1 March 2021
- Published by Elsevier in Heart Rhythm
- Vol. 18 (3) , 473-481
Cybersecurity: The need for data and patient safety with cardiac implantable electronic devices
- 1 March 2021
- Published by Elsevier in Heart Rhythm
- Vol. 18 (3) , 473-481
Cybersecurity: The need for data and patient safety with cardiac implantable electronic devices
- 2 August 2020
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 61 (3) , 461-468
Does the use of intracardiac echocardiography during atrial fibrillation catheter ablation improve outcomes and cost? A nationwide 14-year analysis from 2001 to 2014
Background Intracardiac echocardiography (ICE) use during catheter ablation of atrial fibrillation (AF) provides real-time information to guide transseptal access, for monitoring the ablation and recognition of pericardial bleed. We describe trends of ICE use, impact on complications, and its in-hospital outcomes. Methods The national in-patient sample database was queried from 2001 to 2014 for diagnosis of AF based on ICD-9-CM 427.31 with a catheter ablation procedure code (37.34) in the same hospitalization and its associated complications. ICE was identified using ICD-9-CM procedure code (37.28). Statistical Analysis System (SAS) was used for analysis. Results There was an estimated total 299,152 patients who underwent AF ablation from 2001 to 2014 of which ICE was used in 46,688 (15.6%) patients. The use of ICE significantly increased from 0.08% in 2001 to 15.7% in 2014. In-hospital mortality was significantly lower in patients in whom ICE was used (0.11% vs 0.54%, p < 0.0001). Complications were 52% lower in procedures using ICE vs without ICE (HR [95%CI]; 0.48 [0.44–0.51]). The rate of cardiac complications was also lower in ICE users (3.67% vs 4.51%; p = 0.025). The use of ICE during AF ablation resulted in significantly higher cost of hospitalization ($98,436 ± 597 vs $81,300 ± 310; p < 0.0001), but this was offset by a decreased length of hospital stay (2.1 ± 0.02 vs 4 ± 0.02 days; p < 0.0001). Conclusions The use of ICE during AF ablation has increased over the years and is associated with lower in-hospital mortality and procedural complications, shorter LOS but an increased cost of hospitalization.
- 2 August 2020
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 61 (3) , 461-468
Does the use of intracardiac echocardiography during atrial fibrillation catheter ablation improve outcomes and cost? A nationwide 14-year analysis from 2001 to 2014
Background Intracardiac echocardiography (ICE) use during catheter ablation of atrial fibrillation (AF) provides real-time information to guide transseptal access, for monitoring the ablation and recognition of pericardial bleed. We describe trends of ICE use, impact on complications, and its in-hospital outcomes. Methods The national in-patient sample database was queried from 2001 to 2014 for diagnosis of AF based on ICD-9-CM 427.31 with a catheter ablation procedure code (37.34) in the same hospitalization and its associated complications. ICE was identified using ICD-9-CM procedure code (37.28). Statistical Analysis System (SAS) was used for analysis. Results There was an estimated total 299,152 patients who underwent AF ablation from 2001 to 2014 of which ICE was used in 46,688 (15.6%) patients. The use of ICE significantly increased from 0.08% in 2001 to 15.7% in 2014. In-hospital mortality was significantly lower in patients in whom ICE was used (0.11% vs 0.54%, p < 0.0001). Complications were 52% lower in procedures using ICE vs without ICE (HR [95%CI]; 0.48 [0.44–0.51]). The rate of cardiac complications was also lower in ICE users (3.67% vs 4.51%; p = 0.025). The use of ICE during AF ablation resulted in significantly higher cost of hospitalization ($98,436 ± 597 vs $81,300 ± 310; p < 0.0001), but this was offset by a decreased length of hospital stay (2.1 ± 0.02 vs 4 ± 0.02 days; p < 0.0001). Conclusions The use of ICE during AF ablation has increased over the years and is associated with lower in-hospital mortality and procedural complications, shorter LOS but an increased cost of hospitalization.
- Open Access
- 11 June 2020
- Published by Wiley in Journal of Arrhythmia
- Vol. 36 (4) , 727-734
Trends, burden, and impact of arrhythmia on cardiac amyloid patients: A 16‐year nationwide study from 1999 to 2014
Background: Patients with cardiac amyloidosis (CA) have increased mortality, which can be explained in part by an increased risk of arrhythmias. The burden of arrhythmias in CA, their predictors, and impact on in‐hospital outcomes remains unclear. The role of implantable cardioverter‐defibrillators (ICD) in this population is also uncertain.Methods: We queried the National Inpatient Sample (NIS) using ICD‐9‐CM codes 277.39 and 425.7 to identify CA. Twelve common arrhythmias were extracted using appropriate, validated ICD‐9‐CM codes. ICD implantation was identified using procedure ICD‐9 codes 37.94 to 37.98, 00.51 and 00.54.Results: There were a total of 145,920 CA hospitalizations between 1999 and 2014 in the United States and 56,199 (38.5%) of them were associated with arrhythmias. The prevalence of arrhythmias remained relatively constant from 41.5% in 1999 to 40.2% in 2014. The most common arrhythmia was atrial fibrillation (25.4%). In‐patient mortality was significantly higher in CA patients with arrhythmias (10.4% vs 6.5%, P < .001). ICD implantation was performed in 1,381 (0.94%) patients with CA and analysis revealed an incremental trend in implantation over the study period (0.48% in 1999 to 0.65% in 2014). In‐hospital mortality was significantly lower in patients who underwent ICD implantation (3.7% vs 8%; P = .0078). CA patients with arrhythmias also had an increased cost of hospitalization and length of stay ($65,046 ± 1,079 vs $53,322 ± 687 and 8.3 ± 0.1 vs 7.4 ± 0.1 days, respectively; P < .0001).Conclusion: Cardiac arrhythmias are common in patients with CA and are associated with worse in‐hospital outcomes, increased length of stay, and cost of hospitalization.
- 11 June 2020
- Published by Wiley in Journal of Arrhythmia
- Vol. 36 (4) , 727-734
Open AccessTrends, burden, and impact of arrhythmia on cardiac amyloid patients: A 16‐year nationwide study from 1999 to 2014
Background: Patients with cardiac amyloidosis (CA) have increased mortality, which can be explained in part by an increased risk of arrhythmias. The burden of arrhythmias in CA, their predictors, and impact on in‐hospital outcomes remains unclear. The role of implantable cardioverter‐defibrillators (ICD) in this population is also uncertain.Methods: We queried the National Inpatient Sample (NIS) using ICD‐9‐CM codes 277.39 and 425.7 to identify CA. Twelve common arrhythmias were extracted using appropriate, validated ICD‐9‐CM codes. ICD implantation was identified using procedure ICD‐9 codes 37.94 to 37.98, 00.51 and 00.54.Results: There were a total of 145,920 CA hospitalizations between 1999 and 2014 in the United States and 56,199 (38.5%) of them were associated with arrhythmias. The prevalence of arrhythmias remained relatively constant from 41.5% in 1999 to 40.2% in 2014. The most common arrhythmia was atrial fibrillation (25.4%). In‐patient mortality was significantly higher in CA patients with arrhythmias (10.4% vs 6.5%, P < .001). ICD implantation was performed in 1,381 (0.94%) patients with CA and analysis revealed an incremental trend in implantation over the study period (0.48% in 1999 to 0.65% in 2014). In‐hospital mortality was significantly lower in patients who underwent ICD implantation (3.7% vs 8%; P = .0078). CA patients with arrhythmias also had an increased cost of hospitalization and length of stay ($65,046 ± 1,079 vs $53,322 ± 687 and 8.3 ± 0.1 vs 7.4 ± 0.1 days, respectively; P < .0001).Conclusion: Cardiac arrhythmias are common in patients with CA and are associated with worse in‐hospital outcomes, increased length of stay, and cost of hospitalization.
- 3 April 2014
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 25 (9) , 958-963
Catheter Ablation of Atrial Arrhythmias in Cardiac Sarcoidosis
Ablation of Atrial Arrhythmias in Cardiac Sarcoidosis: Background: We previously reported on the incidence and clinical implications of supraventricular arrhythmia in patients with cardiac sarcoidosis (CS). The role of catheter ablation for the management of atrial arrhythmia (AA) in this patient population is unknown.Methods and Results: One hundred consecutive patients with CS were monitored for the incidence of supraventricular arrhythmias. Those with persistent symptoms despite optimal medical therapy proceeded to catheter ablation. Following ablation, all patients were followed serially with Holter monitoring or device interrogation. Thirty‐two (32%) patients had symptomatic supraventricular arrhythmias. Nine (28%) patients had symptomatic AA requiring catheter ablation for clinical indications. Mean age was 55 ± 11.6 years. Five (56%) patients had atrial fibrillation (AF), of whom 2 also had cavotricuspid isthmus ablation. Four patients had isolated atrial flutter: 2 patients with left atrial flutter, and 2 patients with cavotricuspid flutter. All other arrhythmias were ablated in the left atrium. Mean duration of follow‐up was 1.8 ± 1.9 years. One patient with atypical atrial flutter, and one patient with AF have had recurrence; the remaining patients remain in sinus rhythm.Conclusions: Our study suggests that AA in CS is frequently left atrial in origin. Catheter ablation appears to be effective and safe for the maintenance of sinus rhythm in patients with CS.
- 3 April 2014
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 25 (9) , 958-963
Catheter Ablation of Atrial Arrhythmias in Cardiac Sarcoidosis
Ablation of Atrial Arrhythmias in Cardiac Sarcoidosis: Background: We previously reported on the incidence and clinical implications of supraventricular arrhythmia in patients with cardiac sarcoidosis (CS). The role of catheter ablation for the management of atrial arrhythmia (AA) in this patient population is unknown.Methods and Results: One hundred consecutive patients with CS were monitored for the incidence of supraventricular arrhythmias. Those with persistent symptoms despite optimal medical therapy proceeded to catheter ablation. Following ablation, all patients were followed serially with Holter monitoring or device interrogation. Thirty‐two (32%) patients had symptomatic supraventricular arrhythmias. Nine (28%) patients had symptomatic AA requiring catheter ablation for clinical indications. Mean age was 55 ± 11.6 years. Five (56%) patients had atrial fibrillation (AF), of whom 2 also had cavotricuspid isthmus ablation. Four patients had isolated atrial flutter: 2 patients with left atrial flutter, and 2 patients with cavotricuspid flutter. All other arrhythmias were ablated in the left atrium. Mean duration of follow‐up was 1.8 ± 1.9 years. One patient with atypical atrial flutter, and one patient with AF have had recurrence; the remaining patients remain in sinus rhythm.Conclusions: Our study suggests that AA in CS is frequently left atrial in origin. Catheter ablation appears to be effective and safe for the maintenance of sinus rhythm in patients with CS.
- Open Access
- 1 August 2013
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 6 (4) , e56-e57
Premature Ventricular Contraction-Induced Symptomatic Slow Pathway Conduction Successfully Treated by Catheter Ablation
- 1 August 2013
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 6 (4) , e56-e57
Open AccessPremature Ventricular Contraction-Induced Symptomatic Slow Pathway Conduction Successfully Treated by Catheter Ablation